

## Disclosures

### Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Genentech, Inc	Research/Research Grants ‡ Zebrafish Models of Estrogen Antagonist-Associated Bradycardia	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi-Aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Arrhythmias and Clinical EP</i>
UpToDate	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (2)

Funding Source	Institutional Compensation Level
Cardiology Grand Rounds Director - Beth Israel Deaconess Medical Center	Significant (>= \$5,000)
National Institutes of Health - research grant	Significant (>= \$5,000)

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2021	5-FU Cardiotoxicity	Plaintiff	A young man with colon cancer died suddenly in the setting of 5-FU treatment.	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 9/13/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 9/13/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 9/13/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 9/13/2022

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.